Kiromic BioPharma Inc. logo

Kiromic BioPharma (KRBP) stock

KRBP · Kiromic BioPharma Inc. · NASDAQ

Website

What is the latest news on KRBP stock?

SECago
Kiromic BioPharma Inc. filed SEC Form 8-K: Bankruptcy or Receivership, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

8-K - Kiromic Biopharma, Inc. (0001792581) (Filer)

All KRBP news

When does Kiromic BioPharma report earnings?

The latest Kiromic BioPharma earnings release came out on May 13, 2022: Kiromic BioPharma Reports First Quarter 2022 Financial Results and Recent Corporate Highlights. Before that, Kiromic BioPharma reported on Apr 8, 2022.

KRBP earnings history

Latest news

25 items

Kiromic BioPharma Inc. (KRBP) is a Medicinal Chemicals and Botanical Products company listed on NASDAQ. There were no new wire items for KRBP in the last 30 days. The most recent was published Mar 21, 2025.

Kiromic BioPharma, Inc., a target discovery and gene editing company, focuses on developing immuno-oncology therapeutics for the treatment of blood cancers and solid tumors. The company develops ALEXIS-ISO-1, an allogenic gamma delta CAR-T cell therapy product candidate targeting Isomesothelin; ALEXIS-PRO-1, an allogeneic gamma delta chimeric T cell therapy product candidate targeting PD-L1; and chimeric gamma delta PD1 T cell switch receptor therapy. It has license agreements with Mercer University; CGA 369 Intellectual Holdings, Inc.; and Longwood University, as well as research and development collaboration agreements with Molipharma, S.R.L. and Leon Office (H.K.). The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.

KRBP FAQ

6 questions
  • What does Kiromic BioPharma Inc. do?
    Kiromic BioPharma, Inc., a target discovery and gene editing company, focuses on developing immuno-oncology therapeutics for the treatment of blood cancers and solid tumors. The company develops ALEXIS-ISO-1, an allogenic gamma delta CAR-T cell therapy product candidate targeting Isomesothelin; ALEXIS-PRO-1, an allogeneic gamma delta chimeric T cell therapy product candidate targeting PD-L1; and chimeric gamma delta PD1 T cell switch receptor therapy. It has license agreements with Mercer University; CGA 369 Intellectual Holdings, Inc.; and Longwood University, as well as research and...
  • Where does KRBP stock trade?
    Kiromic BioPharma Inc. (KRBP) is listed on NASDAQ.
  • What sector and industry is KRBP in?
    Kiromic BioPharma Inc. operates in the Health Care sector, Medicinal Chemicals and Botanical Products industry.
  • When did Kiromic BioPharma Inc. go public?
    Kiromic BioPharma Inc. (KRBP) completed its IPO in 2020.
  • What companies are similar to KRBP?
    Notable peers in the same industry include SMFL (Smart for Life Inc.), VLON (Vallon Pharmaceuticals Inc.), MNMD (Mind Medicine (MindMed) Inc.), GRPH (Graphite Bio Inc.), SISI (Shineco Inc.). Compare KRBP side-by-side with any of them on Quantisnow.
  • How can I track KRBP on Quantisnow?
    Quantisnow aggregates Kiromic BioPharma Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow KRBP to receive live email and push alerts on every new disclosure.

Is something on this page wrong, or out of date? Request a change